CN100560073C - 用于治疗病毒感染的n4-酰基胞嘧啶核苷 - Google Patents

用于治疗病毒感染的n4-酰基胞嘧啶核苷 Download PDF

Info

Publication number
CN100560073C
CN100560073C CNB028278402A CN02827840A CN100560073C CN 100560073 C CN100560073 C CN 100560073C CN B028278402 A CNB028278402 A CN B028278402A CN 02827840 A CN02827840 A CN 02827840A CN 100560073 C CN100560073 C CN 100560073C
Authority
CN
China
Prior art keywords
hydrogen
dideoxy
fluorine
nucleoside
flurocytosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028278402A
Other languages
English (en)
Chinese (zh)
Other versions
CN1617726A (zh
Inventor
K·A·瓦塔纳贝
J·史
M·J·奥特托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Pharmasset LLC
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of CN1617726A publication Critical patent/CN1617726A/zh
Application granted granted Critical
Publication of CN100560073C publication Critical patent/CN100560073C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
CNB028278402A 2001-12-14 2002-12-13 用于治疗病毒感染的n4-酰基胞嘧啶核苷 Expired - Fee Related CN100560073C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34155501P 2001-12-14 2001-12-14
US60/341,555 2001-12-14

Publications (2)

Publication Number Publication Date
CN1617726A CN1617726A (zh) 2005-05-18
CN100560073C true CN100560073C (zh) 2009-11-18

Family

ID=23338072

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028278402A Expired - Fee Related CN100560073C (zh) 2001-12-14 2002-12-13 用于治疗病毒感染的n4-酰基胞嘧啶核苷

Country Status (10)

Country Link
US (6) US7105527B2 (US06908924-20050621-C00058.png)
EP (1) EP1569652A4 (US06908924-20050621-C00058.png)
JP (1) JP2005519916A (US06908924-20050621-C00058.png)
KR (1) KR100978904B1 (US06908924-20050621-C00058.png)
CN (1) CN100560073C (US06908924-20050621-C00058.png)
AU (2) AU2002365234B2 (US06908924-20050621-C00058.png)
BR (1) BR0214944A (US06908924-20050621-C00058.png)
CA (1) CA2470255C (US06908924-20050621-C00058.png)
MX (1) MXPA04005779A (US06908924-20050621-C00058.png)
WO (2) WO2003063771A2 (US06908924-20050621-C00058.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
AU2002365234B2 (en) * 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312278A (pt) * 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
CA2494340C (en) 2002-08-01 2012-01-24 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
WO2005097618A2 (en) * 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
US20060084628A1 (en) * 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
US7968703B2 (en) 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103242400B (zh) * 2012-02-08 2016-06-08 河南师范大学 具有抗hiv活性的5-取代嘧啶核苷-噻唑啉酮杂化体及其制备方法
CA2852867C (en) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
KR20230151050A (ko) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13660A (en) * 1855-10-09 Improvements
US3309359A (en) * 1965-10-22 1967-03-14 Hoffmann La Roche N-mono-acyl-5-fluorocytosine derivatives and process
NL8202626A (nl) 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
NL8901258A (nl) 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
DD293498A5 (de) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
JPH05310777A (ja) 1992-05-14 1993-11-22 Yoshitomi Pharmaceut Ind Ltd ２’−デオキシ−２’−メチリデンシチジン化合物
TW254946B (US06908924-20050621-C00058.png) * 1992-12-18 1995-08-21 Hoffmann La Roche
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU4988697A (en) * 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
WO1999026958A1 (en) * 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
KR20030096226A (ko) * 2000-10-13 2003-12-24 샤이어 바이오켐 인코포레이티드 개선된 세포간 전달을 보이는 디옥소란 동족체
BR0114837A (pt) * 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
AU2002365234B2 (en) * 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections

Also Published As

Publication number Publication date
MXPA04005779A (es) 2005-05-16
KR20040094398A (ko) 2004-11-09
CA2470255A1 (en) 2003-08-07
AU2002364730A1 (en) 2003-06-30
WO2003063771A2 (en) 2003-08-07
US20090176730A1 (en) 2009-07-09
AU2002365234B2 (en) 2009-01-29
WO2003051306A2 (en) 2003-06-26
US8114997B2 (en) 2012-02-14
EP1569652A4 (en) 2008-07-02
KR100978904B1 (ko) 2010-08-31
EP1569652A2 (en) 2005-09-07
CN1617726A (zh) 2005-05-18
AU2002364730A8 (en) 2003-06-30
BR0214944A (pt) 2005-06-07
CA2470255C (en) 2012-01-17
US20120202766A1 (en) 2012-08-09
US7105527B2 (en) 2006-09-12
US20030176319A1 (en) 2003-09-18
USRE42015E1 (en) 2010-12-28
WO2003063771A3 (en) 2005-07-07
US6908924B2 (en) 2005-06-21
US20040214844A1 (en) 2004-10-28
US20070078080A1 (en) 2007-04-05
JP2005519916A (ja) 2005-07-07
WO2003051306A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
CN100560073C (zh) 用于治疗病毒感染的n4-酰基胞嘧啶核苷
CA2726588C (en) Compounds and methods for treating inflammatory and fibrotic disorders
CA2969372C (en) Phosphoramidates for the treatment of hepatitis b virus
CN100349913C (zh) 2′－氟代核苷
JP3292830B2 (ja) ２−ヒドロキシメチル−５−（５−フルオロシトシン−１ −イル）−１，３−オキサチオランの抗ウィルス活性および分割
US6875751B2 (en) 3′-prodrugs of 2′-deoxy-β-L-nucleosides
KR100270806B1 (ko) 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
KR100225986B1 (ko) 항바이러스성 누클레오시드 배합제
AU2002365234A1 (en) N4-acylcytosine nucleosides for treatment of viral infections
JPH07500317A (ja) １，３−オキサチオランヌクレオシド類似体
JPH03504969A (ja) ピリミジン誘導体
EP3350191B1 (en) Nucleotide analogs
EA011948B1 (ru) Фосфонатзамещенные пиримидиновые соединения (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
RU2142462C1 (ru) 5-(цитозинил-1-)-1,3-оксатиоланы, способ их получения и фармацевтическая композиция
CN101511185A (zh) 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途
EA036892B1 (ru) Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение
KR20100087241A (ko) 아데포비어 디피복실 오로트산 염 및 이의 제조방법
CN101240001B (zh) 2&#39;-氟代核苷
WO1993017035A1 (en) 2&#39;ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: CGI PHARMACEUTICALS INC

Free format text: FORMER NAME: PHARMASSET INC.

CP03 Change of name, title or address

Address after: American California

Patentee after: Pharmasset Inc.

Address before: new jersey

Patentee before: Pharmasset Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091118

Termination date: 20131213